Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery

Zhou, Kai; Hu, Xiao; Yang, Xuesong; Wu, Yan; Ji, Ke; Ji, Xin; Zhang, Ji; Wu, Xiaojiang; Li, ZhongWu; Wang, Anqiang; Wang, Yusheng; Bu, Zhaode

doi:10.1186/s12885-025-13953-z

Table 2 Univariate overall survival time and disease-free survival time disease-free analysis of clinical and pathological factor

From: Clinicopathologic characteristics and prognostic factors of pure gastric neuroendocrine carcinoma patients undergoing radical surgery

Factors	OS				DFS
Factors	1-year survival rate (%)	3-year survival rate (%)	5-year survival rate (%)	P values	1-year survival rate (%)	3-year survival rate (%)	5-year survival rate (%)	P values
Age(year)				0.026				0.858
≤62	100.0	87.6	78.6		85.0	75.9	70.5
62-70	96.0	71.1	71.1		91.3	75.9	75.9
＞70	87.5	29.2	29.2		85.7	85.7	85.7
Gender				0.879				0.832
Female	100.0	77.1	77.1		81.8	81.8	68.2
Male	95.9	72.6	67.5		89.0	75.8	75.8
Surgical modalities				0.352				0.029
Open surgery	98.1	74.8	70.2		50.0	50.0	50.0
Laparoscopic surgery	85.7	57.1	57.1		92.1	80.5	77.6
Surgical resection modalities				0.345				0.054
Proximal gastrectomy	100.0	62.5	-		100.0	83.3	-
Distal gastrectomy	100.0	90.9	81.8		78.6	53.0	44.2
Total gastrectomy	95.0	69.1	69.1		89.2	86.2	86.2
Neoadjuvant chemotherapy				0.278				0.870
Yes	100.0	66.1	62.0		89.1	78.0	72.0
No	93.5	81.4	76.9		86.2	77.3	77.3
Neoadjuvant chemotherapy regimens				0.006				0.249
EP	100.0	90.0	90.0		100.0	90.0	78.8
SOX/XELOX	100.0	83.3	83.3		100.0	85.7	85.7
Other(IP)	100.0	34.1	22.7		70.0	60.0	60.0
Location of tumor				0.036				0.814
EGJ	96.6	56.2	56.2		89.3	81.2	81.2
Non-EGJ	96.8	88.7	80.4		86.2	74.4	70.0
Greatest dimension				0.586				0.210
＜5cm	95.8	71.8	66.6		86.8	73.9	70.6
≥5cm	100.0	79.5	79.5		90.9	90.9	90.9
CEA (ng/mL)				0.706				0.067
0-5	95.6	74.6	69.0		85.6	72.0	68.6
＞5	100.0	77.8	77.8		100.0	100.0	100.0
CA724(U/mL)			0.601					0.344
0-6.7	95.7	74.9	72.1		86.0	74.6	71.2
＞6.7	100.0	75.0	60.0		100.0	87.5	87.5
Adjuvant chemotherapy				0.392				0.040
Yes	100.0	74.2	71.2		82.3	70.2	66.7
NO	89.5	72.7	65.4		100.0	94.1	94.1
Adjuvant chemotherapy regimens				0.321				0.620
EP	87.5	87.5	87.5		100.0	87.5	75.0
IP	100.0	60.0	60.0		83.3	69.4	69.4
SOX/XELOX	100.0	90.0	90.0		76.9	57.0	57.0
Other	100.0	58.3	43.8		71.4	71.4	71.4
Preoperative correct diagnosis 0.697 0.372
Yes	96.9	70.3	70.3		90.2	81.9	76.8
No	100.0	76.8	68.0		84.4	71.3	71.3
Histology				0.093				0.783
Large cell	100.0	77.9	77.9		81.7	73.8	73.8
Small cell	95.0	73.5	67.9		76.0	76.0	76.0
Mixed type	83.3	50.0	33.3		100.0	75.0	75.0
Mitotic rate（mitoses/mm^2)				0.226				0.030
≤27	93.9	67.0	63.3		93.3	83.7	83.7
＞27	100.0	79.5	73.9		80.0	67.1	61.5
LVI				0.055				0.010
Yes	100.0	60.2	55.2		76.0	61.9	55.7
No	100.0	85.0	81.1		96.8	89.1	89.1
Nerve invasion				0.023				0.009
Yes	96.4	59.2	47.8		77.2	52.7	52.7
No	96.9	83.5	83.5		96.7	89.3	89.3
pT				0.122				0.070
T0-1	100.0	100.0	100.0		100.0	100.0	100.0
T2	100.0	100.0	100.0		100.0	100.0	100.0
T3	97.1	63.7	55.2		81.5	74.5	74.5
T4	92.3	65.8	65.8		90.9	58.4	43.8
pN				＜0.001				0.014
pN0	95.5	95.5	95.5		100.0	100.0	94.4
pN1-3	97.4	59.5	52.2		80.3	62.1	62.1
pTNM				0.001				0.026
0/I	100.0	100.0	100.0		100.0	100.0	100.0
II	97.1	79.7	72.5		87.8	77.1	77.1
III	94.1	38.6	38.6		80.0	38.4	38.4
Cga				0.564				0.405
+	95.2	69.9	63.3		84.4	75.2	71.2
-	100.0	80.4	80.4		94.1	79.9	79.9
CD56				0.532				0.296
+	95.7	71.9	66.8		90.9	80.7	77.3
-	100.0	77.8	77.8		75.0	60.0	60.0
Ki-67 index（%）				0.563				0.455
≤65	100.0	74.1	74.1		92.3	83.9	83.9
＞65	95.7	72.8	67.3		86.0	75.0	71.6

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us